Changes in P-300 latency as a result of co-dergocrine mesylate therapy in patients with senile dementia
✍ Scribed by R. W. Breeze; Sheila Cox; J. Rodgers-Cox
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 331 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0885-6230
No coin nor oath required. For personal study only.
✦ Synopsis
Most studies of the effects of drugs in senile dementia have used subjective rating scales to measure change in mental and cognitive function. Few have used objective measurement. The purpose of this study was to compare the latency of the P-300 component of the event-related auditory evoked potential before and after drug treatment. Twenty-one patients aged 74-93 with dementia defined by a score of > 10 and < 25 using the Mini-Mental Status Test of Folstein were treated with Hydergine 13.5 mg or placebo under double-blind randomized conditions for a period of six weeks. The mean P-300 latency in the active group showed a decrease of 60ms whilst that of the placebo group was prolonged by 25 ms. The difference was statistically significant (p < 0.5) in favour of the active drug. These data suggest that this method of assessment is sensitive to drug-induced changes in patients with senile dementia.
KEY worms-Evoked potential, P-300 latency, co-dergocrine, senile dementia,